• Users Online: 1008
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe News Contacts Login 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 3  |  Issue : 1  |  Page : 7-14

The role of Val66Met single nucleotide polymorphism in brain-derived neurotropic factor gene in prediction of adverse outcomes after ST-segment elevation myocardial infarction


1 Department of Prevention and Treatment of Emergency Conditions, “L. T. Malaya Therapy National Institute NAMSU”, Kharkiv, Ukraine
2 Department of Internal Medicine, Therapeutic Unit, State Medical University of Zaporozhye, Zaporozhye, Ukraine
3 Department of Clinical, Social and Child Psychiatry, Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine; Department of Clinical Neurology, Psychiatry and Narcology, V. N. Karazin's Kharkiv National University, Kharkiv, Ukraine

Correspondence Address:
Prof. Alexander E Berezin
Department of Internal Medicine, Therapeutic Unit, State Medical University of Zaporozhye, 26, Mayakovsky av., Zaporozhye, UA-69035
Ukraine
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/hm.hm_40_19

Rights and Permissions

Background: The single nucleotide polymorphism of Val66Metgen of the brain-derived neurotrophic factor (BDNF) gene is a possible candidate that is associated with the development of psychopathology and combines it with cardiovascular events. The purpose of this study was to research the possible associations of single-nucleotide polymorphism of Val66Met BDNF gene with the occurrence of endpoints after 6 months of follow-up after ST-segment elevation myocardial infarction (STEMI). Materials and Methods: 256 acute STEMI patients after successful primary percutaneous coronary intervention (PCI) were enrolled in the study. Thrombolysis in myocardial infarction III blood flow restoring through culprit artery was determined. The study of single-nucleotide polymorphism of Val66Met gene BDNF (rs6265) was performed by real-time polymerase chain reaction. The emotional state of the patients and its relationship with stress were assessed with the questionnaire “Depression, Anxiety, and Stress-21”. Results: The frequency of genotypes Val66Met gene for BDNF in STEMI patients (n = 256) was the following: 66ValVal = 74.2% (n = 190), 66ValMet + 66MetMet - 25.8% (n = 66). The 66ValMet + 66MetMet polymorphism in the BDNF gene, stress, and anxiety on 10–14 days before the event, as well as reduced left ventricular ejection fraction, were independently associated with combined 6 months' clinical endpoint after STEMI. Conclusion: The Val66Met polymorphism in BDNF gene was found as an independent predictor for combined 6-month clinical endpoints after acute STEMI-treated primary PCI.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2534    
    Printed119    
    Emailed0    
    PDF Downloaded179    
    Comments [Add]    
    Cited by others 2    

Recommend this journal